- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
Panbela Therapeutics is a biotechnology business based in the US. Panbela Therapeutics shares (PBLA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.35 – an increase of 7.38% over the previous week. Panbela Therapeutics employs 7 staff and has a market cap (total outstanding shares value) of 0.00.
What's in this guide?
Our top picks for where to buy Panbela Therapeutics stock
- Trade $0 commission stocks, ETFs, and options with as little as $1
- After-hours trading available
- Earn 4.5% interest on uninvested cash with Gold
- 24/7 customer support
- $0 commission trading
- Instant withdrawals with a 1.75% fee
- Supports 250+ cryptocurrencies
- High-yield account earns up to 4.65% APY
Disclaimer: This page is not financial advice or an endorsement of digital assets, providers or services. Digital assets are volatile and risky, and past performance is no guarantee of future results. Potential regulations or policies can affect their availability and services provided. Talk with a financial professional before making a decision. Finder or the author may own cryptocurrency discussed on this page.
How to buy Panbela Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – PBLA. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Panbela Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Panbela Therapeutics stock price (NASDAQ: PBLA)
Use our graph to track the performance of PBLA stocks over time.Panbela Therapeutics shares at a glance
Latest market close | $0.35 |
---|---|
52-week range | $0.30 - $38.00 |
50-day moving average | $0.36 |
200-day moving average | $0.51 |
Wall St. target price | $500.00 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-34.51 |
Is it a good time to buy Panbela Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Panbela Therapeutics price performance over time
Historical closes compared with the close of $0.3492 from 2024-11-22
1 week (2024-11-15) | 7.38% |
---|---|
1 month (2024-10-24) | 4.77% |
3 months (2024-08-23) | 1.22% |
6 months (2024-05-23) | -8.11% |
1 year (2023-11-22) | -31.66% |
---|---|
2 years (2022-11-23) | -99.99% |
3 years (2021-11-23) | 44880 |
5 years (2019-11-22) | 102000 |
Panbela Therapeutics financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -128.31% |
Return on equity TTM | -798.16% |
Profit margin | 0% |
Book value | $-9.81 |
Market Capitalization | $1.7 million |
TTM: trailing 12 months
Panbela Therapeutics share dividends
We're not expecting Panbela Therapeutics to pay a dividend over the next 12 months.
Have Panbela Therapeutics's shares ever split?
Panbela Therapeutics's shares were split on a 1:20 basis on 17 January 2024 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Panbela Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Panbela Therapeutics shares which in turn could have impacted Panbela Therapeutics's share price.
Panbela Therapeutics share price volatility
Over the last 12 months, Panbela Therapeutics's shares have ranged in value from as little as $0.3 up to $38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Panbela Therapeutics's is 0.944. This would suggest that Panbela Therapeutics's shares are less volatile than average (for this exchange).
Panbela Therapeutics overview
Panbela Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020.
Frequently asked questions
What percentage of Panbela Therapeutics is owned by insiders?Currently 0.001% of Panbela Therapeutics shares are held by insiders. How many people work for Panbela Therapeutics?
Latest data suggests 7 work at Panbela Therapeutics. When does the fiscal year end for Panbela Therapeutics?
Panbela Therapeutics's fiscal year ends in December. Where is Panbela Therapeutics based?
Panbela Therapeutics's address is: 712 Vista Boulevard, Waconia, MN, United States, 55387 What is Panbela Therapeutics's ISIN number?
Panbela Therapeutics's international securities identification number is: US69833W1071
More guides on Finder
-
Best Paper Trading Apps to Practice Trading With Fake Money in 2024
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
-
5 Best International Stock Brokers to Invest in Foreign Assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 Best Discount Brokers of 2024 for Low-Cost Trading
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
9 Best Robo-Advisors for Automatic Investing
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Betterment alternatives
5 Betterment robo-advisor alternatives to consider when building your portfolio.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to gift stock
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
-
Acorns review 2024
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.
Ask a question